Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT00662740. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.
Study identification
- NCT ID
- NCT00662740
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
- Tiotropium/Salmeterol QD Drug
- Placebo Drug
- Salmeterol Drug
- Tiotropium/Salmeterol QD+ Salmeterol Drug
- Tiotropium (Spiriva®) Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2008 (Actual)
- Primary completion
- Nov 21, 2008 (Actual)
- Completion
- Nov 21, 2008 (Actual)
- Last update posted
- Aug 23, 2023
2008
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1184.14.01013 Boehringer Ingelheim Investigational Site | Boulder | Colorado | — | — |
| 1184.14.01018 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1184.14.01006 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1184.14.01003 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1184.14.01015 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 1184.14.01007 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 1184.14.01005 Boehringer Ingelheim Investigational Site | Bangor | Maine | — | — |
| 1184.14.01020 Boehringer Ingelheim Investigational Site | Edina | Minnesota | — | — |
| 1184.14.01009 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 1184.14.01002 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1184.14.01021 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1184.14.01012 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1184.14.01017 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1184.14.01008 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1184.14.01014 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1184.14.01022 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1184.14.01001 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1184.14.01010 Boehringer Ingelheim Investigational Site | Temple | Texas | — | — |
| 1184.14.01011 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1184.14.01019 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00662740, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00662740 live on ClinicalTrials.gov.